The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Autor: Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen, Pernille Wehn, Tressa Hood, Namratha Ram, Wesley Buckingham, Sean Ferree, Bent Ejlertsen

Publikováno v: Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)

Abstract Background The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophospham

Externí odkaz: https://doaj.org/article/4673ff5f6aca4466993ba61ac60353e3

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Autor: Wesley Buckingham, Tressa Hood, Maj-Britt Jensen, Torsten O. Nielsen, Sean Ferree, Bent Ejlertsen, Jens Ole Eriksen, Namratha Ram, Pernille Wehn, Anne-Vibeke Lænkholm

Publikováno v: Breast Cancer Research : BCR
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Jensen, M B, Lænkholm, A V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast Cancer Research, vol. 20, no. 1, 79 . https://doi.org/10.1186/s13058-018-1012-0
Jensen, M-B, Lænkholm, A-V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast cancer research : BCR, vol. 20, 79 . https://doi.org/10.1186/s13058-018-1012-0

Background: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-base

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ebc60b35a91865bcdefe96f09c11184
http://europepmc.org/articles/PMC6062869

Denaturing fixatives are compatible with the NanoString nCounter

Autor: Roman, Rouzier, Aurelie, Roulot, Arthur H, Jeiranian, Namratha, Ram, Jean Marc, Guinebretiere, Anne Vincent, Salomon, David, Gentien

Publikováno v: New biotechnology. 36

The objective of this study was to establish that the denaturing fixative, formalin and acetic acid (AFA), is equivalent to neutral-buffered formalin (NBF) on the nCounter system using the Prosigna assay. Twenty-five previously resected tumors from b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::00520fca95898078a7bb57671750a1c4
https://pubmed.ncbi.nlm.nih.gov/28069519

Abstract A49: Building a comprehensive view of tumor biology in breast cancer by combining NanoString's Prosigna assay with the Pancancer Pathways, Immune Profiling, and Progression Panels

Autor: Joseph M. Beechem, Nathan A. Elliot, Lucas Dennis, Maribeth Eagan, Christina Bailey, Andrew White, Namratha Ram, Patrick Danaher, Rich Boykin, Gayathri Balasundaram, Sean Ferree, Arthur Jeiranian, Seely Kaufmann, Lindy Irving, Wesley Buckingham

Publikováno v: Molecular Cancer Research. 14:A49-A49

Recent advances in molecular profiling of breast cancer have given clinicians the tools required to make better treatment decisions for patients. Building an accurate representation of the biology of a particular tumor is key for: patient selection,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5280817ed81e52ff7701f10a97048078
https://doi.org/10.1158/1557-3125.advbc15-a49